Alpha-Cypermethrin

Alpha-Cypermethrin

SCHEMBL942094

CC1(C)C(C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 1.00
ALDH1A1 P00352 1/20 1.00
LMNA P02545 3/20 0.58
ATM Q13315 3/20 0.58
ADRA2A P08913 1/20 0.58
CNR1 P21554 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
PTGS1 P23219 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2D6 P10635 1/20 0.41
ALOX5 P09917 1/20 0.39
TSHR P16473 3/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
AKR1C3 P42330 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Cypermethrin SCHEMBL5074418 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Beta-Cypermethrin SCHEMBL5934059 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1088177 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL120157 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL942530 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL4338885 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1088295 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1086935 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL11344290 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A
Alpha-Cypermethrin SCHEMBL1087559 1.00 TDP1 (1.00) TDP1ALDH1A1LMNAATMADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CHILDREN'S MEDICAL CENTER CORPORATION 2011-01-06 US claimed
EP-1889028-A1 METHOD FOR DETERMINING PESTICIDE RESIDUES IN SOIL OR PLANT MATERIAL BASF AKTIENGESELLSCHAFT (DE) 2008-02-20 EP claimed
WO-2006125644-A1 METHOD FOR DETERMINING PESTICIDE RESIDUES IN SOIL OR PLANT MATERIAL BASF AKTIENGESELLSCHAFT (DE) 2006-11-30 WO claimed
US-4668511-A PHOTOSTABILITY, PYRETHRINOID, BACULOVIRUS INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 1987-05-26 US claimed
US-20190022084-A1 PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION CHILDREN'S MEDICAL CENTER CORPORATION (US) 2019-01-24 US disclosed
US-10117866-B2 Promoting axon regeneration in the adult CNS through control of protein translation CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-11-06 US disclosed
EP-2502623-B1 Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation CHILDRENS MEDICAL CENTER (US) 2016-04-06 EP disclosed
US-20140213609-A1 PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION CHILDREN'S MEDICAL CENTER CORPORATION (US) 2014-07-31 US disclosed
US-8728756-B2 Promoting axon regeneration in the adult CNS through control of protein translation CHILDREN'S MEDICAL CENTER CORPORATION (US) 2014-05-20 US disclosed
US-20130123228-A1 PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION CHILDREN'S MEDICAL CENTER CORPORATION (US) 2013-05-16 US disclosed
US-8367352-B2 Promoting axon regeneration in the adult CNS through control of protein translation CHILDREN'S MEDICAL CENTER CORPORATION (US) 2013-02-05 US disclosed
US-20130012578-A1 Novel Formulations of Bifenthrin and Enriched Cypermethrin FMC CORPORATION (US) 2013-01-10 US disclosed
WO-2006125647-A1 METHOD FOR DETERMINING RESIDUES IN PLASTICS BASF AKTIENGESELLSCHAFT (DE) 2006-11-30 WO disclosed
WO-2006125644-A1 METHOD FOR DETERMINING PESTICIDE RESIDUES IN SOIL OR PLANT MATERIAL BASF AKTIENGESELLSCHAFT (DE) 2006-11-30 WO disclosed
WO-2000002453-A1 PESTICIDAL COMPOSITION COMPRISING EMAMECTIN NOVARTIS AG (CH) 2000-01-20 WO disclosed
EP-0900024-A1 PESTICIDAL COMPOSITIONS Novartis AG (CH) 1999-03-10 EP disclosed
WO-1997040692-A1 PESTICIDAL COMPOSITIONS NOVARTIS AG (CH) 1997-11-06 WO disclosed
US-5028731-A Reaction Of An Alpha-Hydroxyphenoxyphenylacetonitrile With A Cyclopropanecarbonyl Chloride Without Use Of An Acid Acceptor To Enhance Production Of Insecticidally Active Isomers FMC CORPORATION (US) 1991-07-02 US disclosed
US-4308279-A STEREOISOMERS FMC CORPORATION (US) 1981-12-29 US disclosed
US-4181735-A A-CYANO-3-PHENOXY-BENZYL 2,2-DIMETHYL-3-(2',2'-DIBROMO- OR DICHLORO-VINYL)-CYCLOPROPANE-1-CARBOXYLATE ROUSSEL UCLAF (FR) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002877-A1 PTEN Inhibitors Treat Neutropenia-Associated Pneumonia CSF3R, CSF1R, ATM TDP1 1904/4885ALDH1A1 4692/4885LMNA 3952/4885
US-20130123228-A1 PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION GAP43, BDNF, DCX TDP1 2251/4885ALDH1A1 3775/4885LMNA 2659/4885
US-20190022084-A1 PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION GAP43, BDNF, PMP22 TDP1 2350/4885ALDH1A1 4552/4885LMNA 1777/4885
US-20140213609-A1 PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION GAP43, DCX, BDNF TDP1 2593/4885ALDH1A1 3981/4885LMNA 2349/4885
US-10117866-B2 Promoting axon regeneration in the adult CNS through control of protein translation GAP43, BDNF, DCX TDP1 2251/4885ALDH1A1 3775/4885LMNA 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.